Header Logo

Connection

John Somberg to United States

Back to Details
This is a "connection" page, showing publications John Somberg has written about United States.
John Somberg
Connection Strength
3.309
United States
  1. The Bretylium Saga: A Novel "Old Drug" for Cardiac Resuscitation. Am J Cardiol. 2020 05 15; 125(10):1596-1598.
    View in: PubMed
    Score: 0.111
  2. OUS results, clinical studies and therapeutic innovation in America. Am J Ther. 2014 Jul-Aug; 21(4):233.
    View in: PubMed
    Score: 0.075
  3. Courts, patents, litigation & patient care. Am J Ther. 2014 May-Jun; 21(3):142.
    View in: PubMed
    Score: 0.074
  4. Assessment of cardiovascular and noncardiovascular medical device recalls. Am J Cardiol. 2014 Jun 01; 113(11):1899-903.
    View in: PubMed
    Score: 0.074
  5. The conflict of interest charade. Am J Ther. 2013 Nov-Dec; 20(6):591.
    View in: PubMed
    Score: 0.072
  6. The Supremes got it right. Am J Ther. 2013 Jul-Aug; 20(4):315.
    View in: PubMed
    Score: 0.070
  7. A perspective on the support of scientific research. Am J Ther. 2013 May-Jun; 20(3):231.
    View in: PubMed
    Score: 0.069
  8. Conflating the approval process and clinical research with pharmacoeconomic evaluation. Am J Ther. 2013 Jan; 20(1):1.
    View in: PubMed
    Score: 0.068
  9. Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
    View in: PubMed
    Score: 0.067
  10. Making America more competitive: a paradigm shift in drug and device development. Am J Ther. 2012 Sep; 19(5):315-6.
    View in: PubMed
    Score: 0.066
  11. Drug shortages and ensuring the U.S. supply of needed pharmaceuticals. Am J Ther. 2012 Mar; 19(2):65.
    View in: PubMed
    Score: 0.064
  12. The device development pinata. Am J Ther. 2011 Sep; 18(5):339.
    View in: PubMed
    Score: 0.062
  13. Are we facilitating therapeutic innovation? Am J Ther. 2011 Jul; 18(4):279.
    View in: PubMed
    Score: 0.061
  14. Has the food and drug administration changed the drug approval process? Am J Ther. 2011 May; 18(3):179.
    View in: PubMed
    Score: 0.060
  15. Inappropriate attack on device development. Am J Ther. 2011 Mar-Apr; 18(2):91.
    View in: PubMed
    Score: 0.060
  16. Unfinished business in health care reform. Am J Ther. 2011 Jan; 18(1):1.
    View in: PubMed
    Score: 0.059
  17. The Food and Drug Administration's paternalism. Am J Ther. 2010 Nov-Dec; 17(6):533-4.
    View in: PubMed
    Score: 0.058
  18. Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 Jul-Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.057
  19. Device safety and effectiveness. Am J Ther. 2010 Jul-Aug; 17(4):357.
    View in: PubMed
    Score: 0.057
  20. Is the device development process adequate. Am J Ther. 2010 Mar-Apr; 17(2):123-4.
    View in: PubMed
    Score: 0.056
  21. Medical isotope shortages. Am J Ther. 2009 Sep-Oct; 16(5):378.
    View in: PubMed
    Score: 0.054
  22. Health care reform. Am J Ther. 2009 Jul-Aug; 16(4):281-2.
    View in: PubMed
    Score: 0.053
  23. The extrapolation of study results in the device approval process. Am J Cardiol. 2009 May 01; 103(9):1323-4.
    View in: PubMed
    Score: 0.052
  24. The stimulus package and medical therapeutics. Am J Ther. 2009 Mar-Apr; 16(2):105.
    View in: PubMed
    Score: 0.052
  25. The management of acute heart failure and diuretic therapy. Am J Ther. 2009 Jan-Feb; 16(1):93-7.
    View in: PubMed
    Score: 0.051
  26. Securing the US pharmaceutical supply. Am J Ther. 2008 May-Jun; 15(3):197.
    View in: PubMed
    Score: 0.049
  27. Incidence and predictors of screen failures due to positive urine tests for alcohol, drugs of abuse, and cotinine among normal healthy research volunteers (NHRVs): analysis of data from 687 NHRVs screened at a large clinical pharmacology unit in the United States. Am J Ther. 2008 May-Jun; 15(3):214-20.
    View in: PubMed
    Score: 0.049
  28. FDA user fees and innovation. Am J Ther. 2008 Mar-Apr; 15(2):97.
    View in: PubMed
    Score: 0.048
  29. Mandatory post marketing studies. Am J Ther. 2007 Jul-Aug; 14(4):321.
    View in: PubMed
    Score: 0.046
  30. Patent foramen ovale closure devices: thoughts from the circulatory device advisory panel. Am J Cardiol. 2007 Sep 01; 100(5):905-6.
    View in: PubMed
    Score: 0.046
  31. Biologic generics. Am J Ther. 2007 May-Jun; 14(3):230.
    View in: PubMed
    Score: 0.046
  32. The drug safety review process. Am J Ther. 2007 Mar-Apr; 14(2):119.
    View in: PubMed
    Score: 0.045
  33. The report of the Institute of Medicine on drug safety. Am J Ther. 2007 Jan-Feb; 14(1):1-2.
    View in: PubMed
    Score: 0.045
  34. Off-label promotion. Am J Ther. 2006 Sep-Oct; 13(5):387.
    View in: PubMed
    Score: 0.044
  35. Surrogate endpoints and drug approval. Am J Ther. 2006 Sep-Oct; 13(5):388.
    View in: PubMed
    Score: 0.044
  36. Pharmaceutical companies and medical therapeutics education. Am J Ther. 2006 Mar-Apr; 13(2):93.
    View in: PubMed
    Score: 0.042
  37. An opportunity to distance the FDA from Washington politics. Am J Ther. 2005 Nov-Dec; 12(6):475.
    View in: PubMed
    Score: 0.041
  38. Nesiritide: the wrong controversy. Am J Ther. 2005 Sep-Oct; 12(5):377-8.
    View in: PubMed
    Score: 0.041
  39. Intellectual property. Am J Ther. 2005 Jul-Aug; 12(4):285.
    View in: PubMed
    Score: 0.040
  40. The new drug evaluation process: risk benefit ratio. Am J Ther. 2005 May-Jun; 12(3):199-200.
    View in: PubMed
    Score: 0.040
  41. Lessons learned from the COX-2 advisory hearings. Am J Ther. 2005 Mar-Apr; 12(2):105.
    View in: PubMed
    Score: 0.039
  42. The provisional approval step. Am J Ther. 2005 Jan-Feb; 12(1):1-2.
    View in: PubMed
    Score: 0.039
  43. The politics of therapeutics. Am J Ther. 2004 Nov-Dec; 11(6):422.
    View in: PubMed
    Score: 0.038
  44. Drug trial registries. Am J Ther. 2004 Sep-Oct; 11(5):327.
    View in: PubMed
    Score: 0.038
  45. What is a journal. Am J Ther. 2004 Jul-Aug; 11(4):243.
    View in: PubMed
    Score: 0.038
  46. Obesity therapeutics in the shadows: editorial. Am J Ther. 2004 May-Jun; 11(3):155.
    View in: PubMed
    Score: 0.037
  47. Should statins go OTC. Am J Ther. 2004 Jan-Feb; 11(1):1-2.
    View in: PubMed
    Score: 0.036
  48. Therapeutics, drug pricing and innovation. Am J Ther. 2003 Nov-Dec; 10(6):381.
    View in: PubMed
    Score: 0.036
  49. Clinical trials registries. Am J Ther. 2003 Sep-Oct; 10(5):309-10.
    View in: PubMed
    Score: 0.035
  50. SARS challenges therapeutics. Am J Ther. 2003 May-Jun; 10(3):161.
    View in: PubMed
    Score: 0.035
  51. Hypertension therapeutics in turmoil. Am J Ther. 2003 Mar-Apr; 10(2):81-2.
    View in: PubMed
    Score: 0.034
  52. Free exchange of ideas. Am J Ther. 2003 Jan-Feb; 10(1):1.
    View in: PubMed
    Score: 0.034
  53. Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2002 Nov 01; 90(9):964-8.
    View in: PubMed
    Score: 0.033
  54. Biologic problems. Am J Ther. 2002 Nov-Dec; 9(6):471.
    View in: PubMed
    Score: 0.033
  55. Restricting physician prescribing. Am J Ther. 2002 Sep-Oct; 9(5):369.
    View in: PubMed
    Score: 0.033
  56. Old drugs, new bottles, therapeutic advantage? Am J Ther. 2002 Jul-Aug; 9(4):273-4.
    View in: PubMed
    Score: 0.033
  57. Clinical research oversight. Am J Ther. 2002 Mar-Apr; 9(2):85.
    View in: PubMed
    Score: 0.032
  58. The generic conundrum. Am J Ther. 2002 Mar-Apr; 9(2):87-8.
    View in: PubMed
    Score: 0.032
  59. Bioterrorism 2002. Am J Ther. 2002 Jan-Feb; 9(1):3.
    View in: PubMed
    Score: 0.032
  60. A challenge to America. Am J Ther. 2001 Nov-Dec; 8(6):383.
    View in: PubMed
    Score: 0.031
  61. A new therapeutic millennium [correction of millenium]. Am J Ther. 2001 Nov-Dec; 8(6):385-6.
    View in: PubMed
    Score: 0.031
  62. Stem-cell research. Am J Ther. 2001 Sep-Oct; 8(5):307.
    View in: PubMed
    Score: 0.031
  63. Do we need to accredit clinical research? Am J Ther. 2001 Jul-Aug; 8(4):223-4.
    View in: PubMed
    Score: 0.030
  64. Proposed product labeling changes: does it really matter? Am J Ther. 2001 May-Jun; 8(3):145-6.
    View in: PubMed
    Score: 0.030
  65. Are we overregulated? Am J Ther. 2001 Jan-Feb; 8(1):1-2.
    View in: PubMed
    Score: 0.029
  66. A choice, not an echo. Am J Ther. 2000 Sep; 7(5):281.
    View in: PubMed
    Score: 0.029
  67. Is clinical research oversight adequate in the United States? Am J Ther. 2000 Sep; 7(5):283-4.
    View in: PubMed
    Score: 0.029
  68. Adverse drug reaction reporting. Am J Ther. 2000 Aug; 7(4):227-8.
    View in: PubMed
    Score: 0.029
  69. Medical judgment and therapeutics. Am J Ther. 1999 Nov; 6(6):291-2.
    View in: PubMed
    Score: 0.027
  70. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process. Am J Ther. 1999 May; 6(3):175-8.
    View in: PubMed
    Score: 0.026
  71. Reactions to prescribed drugs kill thousands annually. Am J Ther. 1998 May; 5(3):133.
    View in: PubMed
    Score: 0.024
  72. Sharing regulatory review costs. J Clin Pharmacol. 1992 Oct; 32(10):867.
    View in: PubMed
    Score: 0.017
  73. The treatment of ventricular rhythm disturbances. Am Heart J. 1986 Jun; 111(6):1162-76.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.